Researchers identify gut’s role in peripheral serotonin production and shaping the nervous system.

Although serotonin is well known as a brain neurotransmitter, it is estimated that 90 percent of the body’s serotonin is made in the digestive tract. In fact, altered levels of this peripheral serotonin have been linked to diseases such as irritable bowel syndrome, cardiovascular disease, and osteoporosis. The opensource study published in the journal Cell, shows that certain bacteria in the gut are important for the production of peripheral serotonin.
More and more studies are showing that mice or other model organisms with changes in their gut microbes exhibit altered behaviours state the team, adding that they are interested in how microbes communicate with the nervous system. To start, the researcher explored the idea that normal gut microbes could influence levels of neurotransmitters in their hosts.
The researchers explain that peripheral serotonin is produced in the digestive tract by enterochromaffin (EC) cells and also by particular types of immune cells and neurons. The team first wanted to know if gut microbes have any effect on serotonin production in the gut and, if so, in which types of cells. They began by measuring peripheral serotonin levels in mice with normal populations of gut bacteria and also in germ-free mice that lack these resident microbes.
The data finding showed that the EC cells from germ-free mice produced approximately 60 percent less serotonin than did their peers with conventional bacterial colonies. When these germ-free mice were recolonized with normal gut microbes, the serotonin levels went back up, showing that the deficit in serotonin can be reversed. EC cells are rich sources of serotonin in the gut. What the researchers saw in this experiment is that they appear to depend on microbes to make serotonin, or at least a large portion of it.
The researchers next wanted to find out whether specific species of bacteria, out of the diverse pool of microbes that inhabit the gut, are interacting with EC cells to make serotonin.
After testing several different single species and groups of known gut microbes, the team observed that one condition, the presence of a group of approximately 20 species of spore-forming bacteria, elevated serotonin levels in germ-free mice. The mice treated with this group also showed an increase in gastrointestinal motility compared to their germ-free counterparts, and changes in the activation of blood platelets, which are known to use serotonin to promote clotting.
Wanting to hone in on mechanisms that could be involved in this interesting collaboration between microbe and host, the researchers began looking for molecules that might be key. They identified several particular metabolites, products of the microbes’ metabolism, that were regulated by spore-forming bacteria and that elevated serotonin from EC cells in culture. Furthermore, increasing these metabolites in germ-free mice increased their serotonin levels.
Previous studies have indicated that some bacteria can make serotonin all by themselves. However, this new study suggests that much of the body’s serotonin relies on particular bacteria that interact with the host to produce serotonin. The team states that the current study demonstrates that microbes normally present in the gut stimulate host intestinal cells to produce serotonin.
The team surmise that while the connections between the microbiome and the immune and metabolic systems are well appreciated, research into the role gut microbes play in shaping the nervous system is an exciting frontier in the biological sciences.
Source: Caltech

Categories
depression, gut bacteria, healthinnovations, immunology, irritable bowel syndrome, metabolism, microbiota, nervous system, neurotransmission, opensource, peripheral serotonin, precursor, second brain, serotonin
Michelle Petersen View All
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.